Cargando…

Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene

BACKGROUND: Hereditary angioedema (HAE) in patients with normal C1 inhibitor (C1-INH) and the c.988A > G (p.Lys330Glu; p.K330E) variant in the plasminogen gene (HAE-PLG) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. Aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bork, Konrad, Wulff, Karin, Witzke, Guenther, Machnig, Thomas, Hardt, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026952/
https://www.ncbi.nlm.nih.gov/pubmed/32066472
http://dx.doi.org/10.1186/s13023-020-1334-8
_version_ 1783498766270070784
author Bork, Konrad
Wulff, Karin
Witzke, Guenther
Machnig, Thomas
Hardt, Jochen
author_facet Bork, Konrad
Wulff, Karin
Witzke, Guenther
Machnig, Thomas
Hardt, Jochen
author_sort Bork, Konrad
collection PubMed
description BACKGROUND: Hereditary angioedema (HAE) in patients with normal C1 inhibitor (C1-INH) and the c.988A > G (p.Lys330Glu; p.K330E) variant in the plasminogen gene (HAE-PLG) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. Aim of this observational, retrospective study is to report about the efficacy of various treatments for acute attacks and long-term prophylaxis. RESULTS: The study included 111 patients with HAE-PLG. Thirteen patients were treated with icatibant for 201 acute swelling attacks. The mean duration of the treated attacks (mean 4.3 h; standard deviation [SD] 2.6 h) was significantly shorter than that of the previous 149 untreated attacks (mean 44.7 h; SD 28.6 h, p < 0.0001). Twelve patients were treated with plasma-derived C1-INH for 74 acute swelling attacks. The duration of the treated attacks (mean 31.5 h; SD 18.6 h) was significantly shorter than that of the previous 129 untreated in the same patients (mean 48.2 h; SD 32.5 h, p < 0.0001). Corticosteroids alone showed good response in 61/268 attacks (8 patients), low response in 82/268 attacks (7 patients), and no response in 125/268 attacks (26 patients). Corticosteroids combined with antihistamines showed good response in 13/309 attacks (4 patients), low response in 150/309 attacks (7 patients), and no response in 146/309 attacks (17 patients). Antihistamines alone were ineffective in all 37 attacks of 5 patients. In 2 patients with imminent asphyxiation due to tongue swelling and partial obstruction of the upper airways fresh frozen plasma was used without clinical response. The mean reduction in attack frequency was 46.3% under progestins (6 patients), 93.9% under tranexamic acid (3 patients) and 83.3% under danazol (3 patients). CONCLUSIONS: For patients with HAE-PLG various treatment options are available, which completely or at least partially reduce attack duration or attack frequency.
format Online
Article
Text
id pubmed-7026952
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70269522020-02-24 Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene Bork, Konrad Wulff, Karin Witzke, Guenther Machnig, Thomas Hardt, Jochen Orphanet J Rare Dis Research BACKGROUND: Hereditary angioedema (HAE) in patients with normal C1 inhibitor (C1-INH) and the c.988A > G (p.Lys330Glu; p.K330E) variant in the plasminogen gene (HAE-PLG) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. Aim of this observational, retrospective study is to report about the efficacy of various treatments for acute attacks and long-term prophylaxis. RESULTS: The study included 111 patients with HAE-PLG. Thirteen patients were treated with icatibant for 201 acute swelling attacks. The mean duration of the treated attacks (mean 4.3 h; standard deviation [SD] 2.6 h) was significantly shorter than that of the previous 149 untreated attacks (mean 44.7 h; SD 28.6 h, p < 0.0001). Twelve patients were treated with plasma-derived C1-INH for 74 acute swelling attacks. The duration of the treated attacks (mean 31.5 h; SD 18.6 h) was significantly shorter than that of the previous 129 untreated in the same patients (mean 48.2 h; SD 32.5 h, p < 0.0001). Corticosteroids alone showed good response in 61/268 attacks (8 patients), low response in 82/268 attacks (7 patients), and no response in 125/268 attacks (26 patients). Corticosteroids combined with antihistamines showed good response in 13/309 attacks (4 patients), low response in 150/309 attacks (7 patients), and no response in 146/309 attacks (17 patients). Antihistamines alone were ineffective in all 37 attacks of 5 patients. In 2 patients with imminent asphyxiation due to tongue swelling and partial obstruction of the upper airways fresh frozen plasma was used without clinical response. The mean reduction in attack frequency was 46.3% under progestins (6 patients), 93.9% under tranexamic acid (3 patients) and 83.3% under danazol (3 patients). CONCLUSIONS: For patients with HAE-PLG various treatment options are available, which completely or at least partially reduce attack duration or attack frequency. BioMed Central 2020-02-17 /pmc/articles/PMC7026952/ /pubmed/32066472 http://dx.doi.org/10.1186/s13023-020-1334-8 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bork, Konrad
Wulff, Karin
Witzke, Guenther
Machnig, Thomas
Hardt, Jochen
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title_full Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title_fullStr Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title_full_unstemmed Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title_short Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
title_sort treatment of patients with hereditary angioedema with the c.988a>g (p.lys330glu) variant in the plasminogen gene
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026952/
https://www.ncbi.nlm.nih.gov/pubmed/32066472
http://dx.doi.org/10.1186/s13023-020-1334-8
work_keys_str_mv AT borkkonrad treatmentofpatientswithhereditaryangioedemawiththec988agplys330gluvariantintheplasminogengene
AT wulffkarin treatmentofpatientswithhereditaryangioedemawiththec988agplys330gluvariantintheplasminogengene
AT witzkeguenther treatmentofpatientswithhereditaryangioedemawiththec988agplys330gluvariantintheplasminogengene
AT machnigthomas treatmentofpatientswithhereditaryangioedemawiththec988agplys330gluvariantintheplasminogengene
AT hardtjochen treatmentofpatientswithhereditaryangioedemawiththec988agplys330gluvariantintheplasminogengene